Digestive Health
Transform your digestion with natural fiber support.
Gut health is widely recognized as an important part of overall wellness. Jyotindra Psyllium Husk is a natural fiber source that supports regularity, helps reduce occasional digestive discomfort, and can become a simple addition to a balanced daily routine.
Whether you are managing occasional irregularity or looking to improve your daily fiber intake, psyllium husk offers a gentle, plant-based way to support digestive wellbeing.
What is psyllium husk and how does it work?
Psyllium husk is a natural dietary fiber derived from the seeds of the Plantago ovata plant. When mixed with water, this soluble fiber swells and forms a gel-like substance.
In the digestive tract, psyllium absorbs liquid, helps soften stool, and adds bulk. This action supports regular bowel movements and may help people who experience occasional constipation or irregularity.
Key benefits for digestive health.
Supports smoother bowel movement by adding natural bulk to stool.
Forms a gel-like fiber matrix that may help you feel fuller for longer.
Helps maintain a balanced fiber intake, supporting overall digestive function.
Soluble fiber may support heart-conscious diets when used with healthy lifestyle habits.
How to include Jyotindra Psyllium Husk in your diet.
Psyllium husk can be mixed with water, juice, smoothies, yogurt, soups, or selected baked recipes. Start with a small serving and gradually increase intake as your body adjusts.
- Mix with sufficient water and consume promptly.
- Drink plenty of fluids throughout the day.
- Add to smoothies or breakfast bowls for an easy fiber boost.
- Use consistently as part of a balanced diet and active lifestyle.
Potential side effects and precautions.
Psyllium husk is generally well tolerated, but some people may experience bloating, gas, or stomach discomfort when first increasing fiber intake. Begin with smaller quantities and increase gradually.
Adequate hydration is important because psyllium absorbs water. People with a history of bowel obstruction, swallowing difficulty, gastrointestinal medical conditions, or those taking regular medication should consult a healthcare professional before use. Pregnant or nursing women should also seek medical advice before adding psyllium husk to their routine.
Clinical Research
Fiber Supplementation, Particularly Psyllium, May Improve Clinical Response in Irritable Bowel Syndrome
TOPLINE
Among people with irritable bowel syndrome (IBS), more than half of those receiving fiber supplementation achieved a clinical response compared with 44% of those receiving placebo. Psyllium was associated with a greater clinical response than control.
METHODOLOGY
Fiber supplements are often recommended as a first-line treatment for IBS, along with lifestyle changes and medications for specific symptoms, and patients usually find this treatment acceptable.
Researchers conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the efficacy of fiber supplements vs placebo in adults with IBS. Eligible trials were conducted in community or outpatient settings.
A total of 30 RCTs, including 1904 adults, were identified; 28 RCTs were included in the meta-analysis.
Fiber types included wheat bran (n = 7), psyllium (n = 6), inulin-type fructans (n = 5), beta-galacto-oligosaccharides (n = 2), and various other fibers. Fiber supplements incorporated into foods were also considered. Treatment durations ranged from 7 days to 3 months, with fiber doses ranging from 1.4 to 30 g/d.
The primary outcome was clinical response to fiber supplements; secondary outcomes were the effects of fiber supplements on gastrointestinal symptoms, stool frequency and consistency, and quality of life.
TAKEAWAY
Clinical response occurred in 52% of participants receiving fiber vs 44% receiving placebo-like control (risk ratio [RR], 1.21; P = .02; I2 = 38%; 16 trials). Psyllium was associated with a greater clinical response than control (RR, 1.53; P = .02; I2 = 54%). Wheat bran did not result in a greater or worse clinical response.
Fiber supplementation was associated with better clinical response than control in subgroup analyses of trials using doses ≤ 10 g/d (RR, 1.29; P = .04), as well as when provided as a supplement (RR, 1.23; P = .02) or in powder or granule form (RR, 1.23; P = .02).
Beta-galacto-oligosaccharides were associated with improved overall gastrointestinal symptoms compared with control (standardized mean difference [SMD], -0.62; P = .02). Fiber given as powder or granules also showed an improvement in symptoms (SMD, -0.33; P = .02).
There was no effect of fiber supplementation on bloating, abdominal pain, flatulence, or quality of life compared to controls. None of the reported common adverse events were attributed to fiber.
IN PRACTICE
"The findings of this systematic review and meta-analysis indicate the efficacy of fiber supplementation in relation to clinical response in IBS. Although overall and symptom-specific effects were limited, the greater global clinical response compared with placebo, particularly with psyllium, supports the continued recommendation of fiber as a first-line therapy for IBS," the authors wrote.
SOURCE
The study was led by Heidi M. Staudacher, PhD, School of Translational Medicine, Monash University, Melbourne, Australia. It was published online on August 14 in Gastroenterology.
LIMITATIONS
The exclusive focus on fiber supplements limited the applicability of the findings. Fewer than half of trials reported adherence, and adverse events were reported in less than 30% of trials. All trials had a moderate or high risk for bias, mainly relating to lack of between-group analyses or intention-to-treat approaches.
DISCLOSURES
One author reported being supported by a National Health and Medical Research Council Investigator Grant and receiving research funding, honoraria, and travel funding from various sources. Another author reported receiving research grants and serving as a consultant, and a third author reported receiving research grants and speaker fees, holding a joint patent for using volatile organic compounds as biomarkers in IBS, and receiving royalties from Wiley Publishing.